Arvinas, Inc. (ARVN)
8.31
+0.15
(+1.84%)
USD |
NASDAQ |
Sep 17, 16:00
8.305
0.00 (0.00%)
Pre-Market: 20:00
Arvinas Cash from Operations (Quarterly) : -48.30M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -48.30M |
| March 31, 2026 | -69.20M |
| December 31, 2025 | -30.40M |
| September 30, 2025 | -59.10M |
| June 30, 2025 | -95.40M |
| March 31, 2025 | -88.90M |
| December 31, 2024 | -84.10M |
| September 30, 2024 | -128.00M |
| June 30, 2024 | 50.30M |
| March 31, 2024 | -97.50M |
| December 31, 2023 | -83.10M |
| September 30, 2023 | -84.80M |
| June 30, 2023 | -88.70M |
| March 31, 2023 | -91.20M |
| December 31, 2022 | -71.20M |
| September 30, 2022 | -66.60M |
| June 30, 2022 | -78.60M |
| March 31, 2022 | -57.10M |
| December 31, 2021 | -35.75M |
| Date | Value |
|---|---|
| September 30, 2021 | 681.53M |
| June 30, 2021 | -47.40M |
| March 31, 2021 | -38.97M |
| December 31, 2020 | -29.02M |
| September 30, 2020 | -22.38M |
| June 30, 2020 | -21.40M |
| March 31, 2020 | -16.95M |
| December 31, 2019 | -16.18M |
| September 30, 2019 | 1.854M |
| June 30, 2019 | -13.57M |
| March 31, 2019 | -12.73M |
| December 31, 2018 | -12.25M |
| September 30, 2018 | -10.99M |
| June 30, 2018 | -12.18M |
| March 31, 2018 | 19.30M |
| December 31, 2017 | 28.16M |
| September 30, 2017 | -7.441M |
| June 30, 2017 | -8.528M |
| March 31, 2017 | -7.076M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -2.536M |
| CNBX Pharmaceuticals, Inc. | -0.0477M |
| GB Sciences, Inc. | -- |
| Fulcrum Therapeutics, Inc. | -16.04M |
| Definium Therapeutics, Inc. | -52.33M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 54.90M |
| Cash from Financing (Quarterly) | 0.40M |
| Free Cash Flow | -208.80M |
| Free Cash Flow Per Share (Quarterly) | -0.7382 |
| Free Cash Flow to Equity (Quarterly) | -48.10M |
| Free Cash Flow to Firm (Quarterly) | -48.50M |
| Free Cash Flow Yield | -37.53% |